hVIVO (LON:HVO) Shares Up 13% - Here's What Happened

Key Points

• hVIVO plc's stock surged by 13% during trading, reaching a high of GBX 8 and closing at GBX 7.80, with a significant increase in trading volume.
• Multiple research firms have issued ratings on hVIVO, with Shore Capital lowering its price target to GBX 25 while Peel Hunt maintained its target at GBX 21, resulting in a consensus rating of "Buy".
• hVIVO reported an earnings per share of GBX (0.29) for the quarter, showing a high return on equity of 47.93% and a net margin of 25.96%.

hVIVO plc (LON:HVO - Get Free Report)'s stock price shot up 13% during trading on Tuesday . The company traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). 9,588,585 shares changed hands during trading, an increase of 223% from the average session volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HVO. Shore Capital cut their price target on shares of hVIVO from GBX 35 to GBX 25 and set a "buy" rating on the stock in a report on Tuesday, September 23rd. Peel Hunt restated an "add" rating and set a GBX 21 price objective on shares of hVIVO in a research report on Tuesday, July 29th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, hVIVO has a consensus rating of "Buy" and a consensus target price of GBX 23.

hVIVO Trading Up 2.6%

The company has a market cap of £54.98 million, a P/E ratio of 1,038.96 and a beta of 0.97. The stock's 50-day moving average is GBX 9.24 and its two-hundred day moving average is GBX 11.96. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. As a group, equities research analysts predict that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.